Stephen V Liu, MD (@StephenVLiu) ranks #1 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 290 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HARMONi-6, DESTINY-Lung04, CROWN. CMS Open Payments lists $131,599 in 2025 general payments.
At a Glance
- 79 posts naming a trial in 2026
- 40 trials discussed by name
- Lung Cancer: US #1, Global #1 · 290 physicians engaged
- Leading physician voice: #1 of 41 physicians on ADAURA; #1 of 37 physicians on DESTINY-Lung04
- Presented at ESMO 2026 in 2026
- CMS Open Payments lists $131,599 in 2025 general payments.
This Month
What Stephen V Liu, MD has posted in the last 30 days. Updated November 10, 2026.
Patterns of progression in ADRIATIC (durvalumab consolidation post CRT for LS-SCLC) @JTOonline. Similar rates of intrathoracic progression but lower extrathoracic progression with durvalumab (20% vs 30%) including brain (6.8% vs 12.4%). https://t.co/G99sag43zG
#ESMO26 Dr. Mary O'Brien presents final analysis of phase III PEARLS/KEYNOTE-091 trial: adjuvant pembrolizumab for resected NSCLC with 87m f/u. In pts who received adjuvant chemo, DFS 58.7 vs 39.1m (HR 0.80) and no difference in survival: OS HR 0.91 with 6y DFS 69% vs 65%. In that group, improved lung cancer specific survival (HR 0.69, 6y rate 82% vs 75%). #ESMOAmbassadors
Important longer follow up from DeLLphi-304 (2L tarlatamab vs SCLC) presented by Dr. @charlesrudin at #ESMO26 simultaneously published @Annals_Oncology. Median PFS 4.2 vs 3.2m, mOS 13.6 vs 8.4m, 2y OS 30% vs 15%, RR 35% vs 20% #ESMOAmbassadors https://t.co/2kvS0rW3ug
#ESMO26 The brilliant Dr. @marinagarassino with biomarker analysis from the phase III KEYNOTE 671 study of perioperative pembrolizumab for resectable NSCLC showing association of T-cell inflamed gene expression profile and TMB with efficacy. Benefit across subgroups; inflamed profile associated with better prognosis. #ESMOAmbassadors
#ESMO26 Dr. Yilong Wu @ThomasW35874311 presents SANOVO: 1L osimertinib + savolitinib/placebo in EGFR+ NSCLC with MET overexpression. Wow. PFS 24.8 vs 11.1m, HR 0.45 with OS 44.5 vs 34.9m, HR 0.48. RR 81% vs 68%. Toxicities below. Very impressive. #ESMOAmbassadors https://t.co/l11IljLSvi
#ESMO26 Dr. Shun Lu gives us the final analysis of the phase III Neotorch trial: perioperative toripalimab + chemotherapy for resectable stage II/III NSCLC. With 48.2m follow up, EFS 0.52 (median NR vs 20), MPR 47% vs 9%, pCR 26% vs 1%, OS HR 0.66. #ESMOAmbassadors https://t.co/4qsvyICFGa
Who Amplifies Stephen V Liu, MD
Physicians who reposted Stephen V Liu, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #1 | #1 | 290 | 754 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Stephen V Liu, MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Poster (2577P)INT-101: Tambotatug Pelitecan (YL201): Efficacy and Safety in Locally Advanced/Metastatic NSCLC From a Phase 1 StudySource: @HHorinouchi on X ↗
- ESMO 2026 · Poster (2529P)TERESA: Real-World Treatment Patterns and Outcomes in Patients With Unresected Stage I-II NSCLCSource: @HHorinouchi on X ↗
- ESMO 2026 · DiscussantDiscussant, DeLLphi-305 (Presidential Symposium 1)
What Colleagues Are Saying About Stephen V Liu, MD
2026 posts by fellow physicians that mention @StephenVLiu, quoted word for word.
🔥 TODAY COULD BE ONE OF THE DEFINING MOMENTS OF #ESMO26! 🔥 The ESMO Presidential Symposium is always one of the highlights of the congress, and today’s session promises some truly extraordinary science! If I had to pick ONE study with the greatest potential to change clinical practice at ESMO 2026, my choice would be DeLLphi-305. For decades, SCLC has been one of the most challenging diseases in oncology, with far too little progress and far too few therapeutic breakthroughs. Could DeLLphi-305 finally represent the major leap forward we have been waiting for? We already know that adding tarlatamab to durvalumab as first-line maintenance significantly improves OS compared with durvalumab alone. But today, we will finally see the numbers. And I am genuinely excited to discover just how transformative this benefit might be! My personal bet for the biggest breakthrough of #ESMO26? DeLLphi-305. @StephenVLiu @sands_jacob Of course, the magnitude of survival benefit, safety and clinical applicability will ultimately determine its impact. But the potential is enormous. Don’t miss today’s Presidential Symposium! Madrid | 🕟 16:30 CEST Alicante auditorium #ESMO26 #ESMOAmbassador #SCLC #LungCancer #Immunotherapy #Oncology #PracticeChanging
#ESMO26 Presidential 1 Excellent state-of-the art discussion on #Dellphi-305 by the 1@only @StephenVLiu emphasizing on: ➡️ 1L maintenance Tarla setting a new SoC with a mOS of>20 months ❓High attrition rate from induction to maintenance, need for earlier TCE ( Dellphi-312) ❌Only 19% of pts in control arm received 2L Tarla post-progression reflecting access hurdles ✅ Global access to Tarla will make innovation meaningful for our patients @@myESMO #ESMOAmbassadors
Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial @sands_jacob . A new chapter in the treatment of ES-SCLC! #ESMO26. One year ago, we anticipated that we might finally be bending gravity. Today, that vision is becoming a reality!!!!!!👏👏👏👏👏 https://t.co/QDMrTH5l8L
Re MARIPOSA trial, thanks @StephenVLiu for important update. Helps define long-term risk versus benefit for this regimen. I am convinced that there is rationale for looking toward the "light at the end of the tunnel". Was data on ctDNA included? @IASLC @isliquidbiopsy https://t.co/Av2Wh07H3E
Pivotal #DeLLphi305 data @sands_jacob 👏, w/ a phenomenal discussion by @StephenVLiu w/ two standout quotes: ⭐️ "Innovation loses impact if it doesn't reach the patients who need it most" ⭐️ "It is not enough to know if the drugs work or how well they work, we need to know why and in whom they work to make better individualized decisions"
A masterclass in how to deliver an outstanding scientific discussion at #ESMO26! 👏 Highly recommend watching @StephenVLiu’s discussion of the incredible DeLLphi-305 results presented by @sands_jacob. What made it so effective? 🔹 Started with the unmet clinical need, not the trial data. 🔹 Critically appraised the evidence while explaining what it means for patients. 🔹 Moved beyond what the trial showed to why it matters and what questions come next. 🔹 Connected efficacy, safety and real-world access into one compelling narrative. 🔹Masterful delivery. Purposeful pauses, variation in tone and pitch, and virtually no filler words. He finished with a powerful reminder: “innovation loses impact if it doesn’t reach the patients who need it most.” A great discussant doesn’t just summarise or repeat results. They help us understand what changes, what remains uncertain and what the field must do next. Science communication at its best! 👏
Trials Stephen V Liu, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HARMONi-6 | 6 | #2 of 74 | May 31, 2026 |
| DESTINY-Lung04 | 5 | #1 of 37 | Oct 24, 2026 |
| CROWN | 4 | #1 of 36 | Oct 24, 2026 |
| TAISHAN-302 | 4 | #1 of 26 | Sep 13, 2026 |
| PERSEE (GFPC 01-2020) | 3 | #3 of 34 | Oct 25, 2026 |
| OptiTROP-Lung06 | 3 | #2 of 29 | Oct 25, 2026 |
| KRASCENDO-1 | 3 | #2 of 49 | Oct 25, 2026 |
| REZILIENT3 | 3 | #5 of 27 | Sep 14, 2026 |
| ADAURA | 3 | #1 of 41 | Sep 13, 2026 |
| MAVERICK (SWOG S1827) | 3 | #1 of 33 | Sep 12, 2026 |
| WU-KONG28 | 3 | #2 of 29 | May 29, 2026 |
| DeLLphi-304 | 2 | #3 of 23 | Oct 26, 2026 |
| KEYNOTE-671 | 2 | #3 of 13 | Oct 26, 2026 |
| PANKU-Lung01 | 2 | #4 of 16 | Oct 26, 2026 |
| LAURA | 2 | #3 of 6 | Oct 10, 2026 |
| MARIPOSA | 2 | #6 of 14 | Sep 27, 2026 |
| ARROS-1 | 2 | #1 of 26 | Sep 14, 2026 |
| PAPILLON | 2 | #1 of 26 | Sep 14, 2026 |
| ARTEMIS-008 | 2 | #2 of 20 | Sep 13, 2026 |
| EVOKE-03 / KEYNOTE-D46 | 2 | #10 of 16 | Sep 13, 2026 |
| LIBRETTO-432 | 2 | #3 of 53 | May 31, 2026 |
| OptiTROP-Lung05 | 2 | #2 of 19 | May 29, 2026 |
| CheckMate-77T | 2 | #1 of 5 | Apr 18, 2026 |
| ADRIATIC | 1 | #3 of 4 | Nov 3, 2026 |
| PEARLS / KEYNOTE-091 | 1 | #2 of 5 | Oct 26, 2026 |
| SANOVO | 1 | #1 of 14 | Oct 26, 2026 |
| Neotorch | 1 | #3 of 6 | Oct 26, 2026 |
| HERON-Lung01 | 1 | #4 of 10 | Oct 26, 2026 |
| OptiTROP-Lung04 | 1 | #4 of 18 | Oct 25, 2026 |
| SARON | 1 | #6 of 22 | Oct 25, 2026 |
| FLAURA2 | 1 | #6 of 25 | Oct 24, 2026 |
| NeoADAURA | 1 | #3 of 3 | Oct 10, 2026 |
| MDT-BRIDGE | 1 | #2 of 18 | Sep 13, 2026 |
| IMpower030 | 1 | #1 of 8 | Sep 13, 2026 |
| SOHO-01 | 1 | #3 of 8 | Sep 9, 2026 |
| DeLLphi-305 | 1 | #18 of 86 | Sep 8, 2026 |
| HARMONi-2 | 1 | #17 of 19 | Sep 3, 2026 |
| AEGEAN | 1 | #4 of 4 | Aug 31, 2026 |
| SKYSCRAPER-01 | 1 | #3 of 3 | Jul 28, 2026 |
| IMforte | 1 | #4 of 12 | May 9, 2026 |
Stephen V Liu, MD on HARMONi-6
Dr. Shun Lu presents HARMONi-6 #ASCO26 plenary: first-line ivonescimab + chemo (carbo + pac) vs tislelizumab + chemo in squamous NSCLC. An unmet need, where long-term survival with standard chemo-IO is uncommon. Will PD-1/VEGFa bispecific improve OS & prove safe in squamous? https://t.co/8oYROCac2H
HARMONi-6 from #ASCO26 plenary to @TheLancet: 1L ivonescimab + chemo vs tislelizumab/chemo in squamous NSCLC (n=761). Ivonescimab shows OS benefit: 27.9 vs 23.7m (HR 0.66) including PD-L1 negative (OS HR 0.64). G3+ bleeding in only 3% vs 1%. https://t.co/zHdxOC42A8
Available now: discussion on HARMONi-6 (1L ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC) from Drs. Tina Cascone and @g_mountzios after #ASCO26 plenary. OS benefit but how generalizable are data and how do we best select patients? https://t.co/bkZDI9MGOY
Stephen V Liu, MD on DESTINY-Lung04
#ESMO26 Dr. Silvia Novello presents PRO endpoints from DESTINY-Lung04 (1L trastuzumab deruxtecan vs chemo-IO in HER2 mutant NSCLC). Time to deterioration in pulmonary symptoms favors T-DXd. PROs comparable between arms, symptoms generally better with T-DXd. #ESMOAmbassadors https://t.co/vPNSb5AEPU
Dr. @JuliaRotow at #WCLC26 with primary results from DESTINY-Lung04: first-line trastuzumab deruxtecan vs platinum + pemetrexed + pembro in advanced HER2 mutant NSCLC. Primary endpoint of PFS favors T-DXd at 14.3 vs 8.3m, HR 0.63 and RR 70% vs 44.5%, DOR 13.7 vs 9.7m, PFS2 22.7 vs 17.3m.
#WCLC26 In DESTINY-Lung04, no OS signal yet. Toxicities led to discontinuation in 16% of both arms. Biggest concern here is the ILD at 20.8% - while most were grade 1/2 and resolved, these are still high rates. This will impact delivery and possibly subsequent therapies... https://t.co/ZUQSd7yaFX
Stephen V Liu, MD on CROWN
#ESMO26 Dr. @bensolomon1 presents ctDNA data from CROWN: 1L lorlatinib in ALK+ NSCLC. Few samples post-progression but no on-target ALK resistance noted, only bypass / off-target. Those with early progression had more baseline mutations. TP53 and clearance were prognostic. https://t.co/DWi1jaj57k
Dr. @TonyMok9 at #ASCO26 presents update on CROWN in ALK+ NSCLC. After 7y, median PFS with lorlatinib still not reached. Between years 5 and 7, only 4 progression events occurred. Unusual but fantastic to see such a tail with targeted therapy - this is truly raising the bar. https://t.co/AvwYIdQ1HB
CROWN update at #ASCO26 now @Annals_Oncology. After 7 years of follow up, median PFS with first-line lorlatinib for ALK+ NSCLC not yet reached! Compared to 9.1m with crizotinib. With lorlatinib, no d/c due to TRAE after 26m & NO intracranial PD after 30m https://t.co/dFSFDfDttN
Stephen V Liu, MD on TAISHAN-302
Dr. Li Zhang presents results from TAISHAN-302: phase III study of tambotatug pelitecan (tam-peli, YL201), a B7-H3 antibody drug conjugate (topo-1 payload, DAR 8) vs topotecan in relapsed SCLC at #WCLC26. Included pts with SCLC progressed after 1 line of platinum-based chemotherapy with a 1:1 randomization to tam-peli 2mg/kg q3w vs standard topotecan. Median f/u ~9m and 71 pts in tam-peli arm still on therapy (vs 8 with topotecan). Note that almost 30% of pts with no smoking history - a pattern we are seeing in ES-SCLC as well. Biology shifting...
Results from phase III TAISHAN-302 study showing massive OS benefit of tam-peli over topotecan in relapsed SCLC @NEJM after #WCLC26 presidential. https://t.co/YK8fg3VK7w
Dr. Li Zhang makes important clarification missed by some on TAISHAN-302: relapsed SCLC, tam peli with superior OS over topotecan. Though ~30% of patients had no smoking history, these are not transformed SCLC - those were excluded. This is a shift in SCLC biology we are seeing - and many are TP52/Rb1 intact. #WCLC26
Stephen V Liu, MD on PERSEE (GFPC 01-2020)
Off the rousing #ESMO26 oral presentation from Dr. @decroisette, the phase III PERSEE trial with simultaneous publication @Annals_Oncology. Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56! https://t.co/l2d3Sdd9CH
#ESMO26 Dr. @decroisette with the important PERSEE trial: pembrolizumab +/- chemotherapy in PDL1 high NSCLC. Enrolled 321 pts in 3y at 28 sites. Pembro-chemo PFS 16.1 vs 6.9m (HR 0.56), better across strata. OS 50.2 vs 29.9m (HR 0.77, ns) - not powered for OS. #ESMOAmbassadors https://t.co/B9NBt7E1bP
#ESMO26 Dr. @benlevylungdoc guides a thoughtful discussion on escalation of therapy for driver negative NSCLC. Notes limitations of current tools to guide proper use of local consolidative radiation. Addition of chemotherapy as done in PERSEE is a real win, even in ultra high. Awaiting other studies, including INSIGNA. #ESMOAmbassadors
Stephen V Liu, MD on OptiTROP-Lung06
OptiTROP-Lung06 now @NEJM after #ESMO26 presentation showing Sac-TMT (TROP2 ADC) + pembro superior to standard chemotherapy + pembro. #ESMOAmbassadors @myESMO https://t.co/AWr8vi6VvR
#ESMO26 Dr. Caicun Zhou presents OptiTROP-Lung06: 1L Sac-TMT (TROP2 ADC) + pembro vs chemo + pembro in non-squamous NSCLC. PFS 15m vs 5.7m (HR 0.49). OS immature but 1y rate 78% vs 66% (HR 0.58). mDOR 13.6m vs 6.8m. TEAEs leading to d/c of drug 6% with Sac-TMT 14% with chemoIO. https://t.co/NuvZZ9S3EM
Phase III OptiTROP-Lung06 meets primary endpoint. First-line sacituzumab tirumotecan (sac-TMT, Trop2 ADC) + pembro vs chemo + pembro in PD-L1 negative non-squamous NSCLC. Sac-TMT + pembro had superior PFS with OS trend. Will ADCs push out chemo? https://t.co/kQiRMDEYN9
Stephen V Liu, MD on KRASCENDO-1
Brilliant discussion from Dr. @BenjaminBesseMD at #ESMO26 on the Krascendo 1 study of divarasib vs sotorasib/adagrasib. Rightly points out lack of crossover in a study with a PFS endpoint as unjust. Excellent points all around. #ESMOAmbassadors https://t.co/AZp29NMYLI
After expertly delivered #ESMO26 plenary, phase III Krascendo 1 study from Dr. @FSkoulidis now @NEJM. Divarasib superior with PFS 9.8m vs 5.7m (HR 0.58) and OS 17.7m vs 12m (HR 0.56). RR 58% vs 32% and DOR 11.9m vs 6.9m. G3-4 TRAEs 25% vs 35%. https://t.co/gZ3slJ3z3I
Top-line results from randomized phase III Krascendo 1 trial shows divarasib superior to first generation KRAS G12C inhibitors with improved PFS and significant improvement in OS, meeting primary endpoint. Eagerly awaiting data presentation! https://t.co/u5RpqQZbto
Stephen V Liu, MD on REZILIENT3
Dr. @danieltanmd presents REZILIENT 3 at #WCLC26: 1L zipalertinib + chemo vs chemo in EGFR exon 20 insertion NSCLC. Superior PFS 14.5 vs 8.5m (HR 0.50) with RR 65% vs 40%. https://t.co/s3yfHfyZF8
#WCLC26 In REZILIENT 3, no separation of OS to date. Safety summary shows dose reduction of zipalertinib in 44%, discontinuation 17%, pneumonitis in 6%. Cytopenias generally early. Another potential option in this disease setting. https://t.co/VIEUgwe9qI
Press release: Phase III REZILIENT3 trial meets its primary endpoint. Adding zipalertinib to first line chemotherapy for advanced NSCLC with an EGFR exon 20 insertion mutation significantly improved PFS over chemo alone. https://t.co/057qHTZCEz https://t.co/HrcZfmeQ1B
Stephen V Liu, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Consensus definition on resectability of stage III NSCLC from @EORTC published @LancetRespirMed. Current consensus is that N3 or bulky N2 is unresectable but multi-station N2 remains potentially resectable. Does not lend itself perfectly to a flowchart given heterogeneity: https://t.co/okClpfOIeP
Dr. @riess_md at #AACR26 updates RMC-9805 (zoldonrasib) in KRAS G12D NSCLC. Very impressive. G12D is a particular need in lung cancer as many patients have no smoking history and do not fare as well with immunotherapy. Zoldonrasib is a mutant selective, RAS(ON) inhibitor. https://t.co/aslGbpWQI1
#ASCO26 With neoadjuvant lorlatinib, pCR 47% and MPR 81%. Amazing. RR 84% and 1y EFS 97%. Down staging of nodes in 90%. Very reassuring and consistency safety results. Phenomenal clinical results. https://t.co/rPvmOmcQsj
Impact of 1L amivantamab + lazertinib vs osimertinib on acquired resistance in EGFR mutant NSCLC @JTOonline. Ami/laz reduces MET amp (3.4% vs 13.1%) and acquired EGFR resistance mts (1.4% vs 7.6%). 2L PFS longer in ami/laz arm vs osi (8.4m vs 5.3m). https://t.co/UYIfOrJEmZ
Dr. @drshieldsmd gives a great discussion on SCLC at #ASCO26. Tarlatamab update shows the drug raises the bar but points out importance of ICANS awareness. Is it higher in its with brain metastases? https://t.co/SbvcQybTlk
Industry Payments
CMS Open Payments · 2025 general payments
$131,599 across 107 payments